Slow-Progressing Patient Subgroup Shows Significant Efficacy and NfL Biomarker Improvement Despite Missing Overall Trial Significance
Corestemchemon has officially submitted a meeting application to the United States Food and Drug Administration (FDA) regarding its amyotrophic lateral sclerosis (ALS) treatment candidate, NeuroNata–R (neuronata-R), according to recent industry disclosures. The regulatory filing marks a significant operational step for the South Korean biotechnology firm as it seeks guidance on the clinical development pathway and … Read more